Kezar Life Sciences (NASDAQ:KZR) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) saw an uptick in trading volume on Thursday . 47,512 shares changed hands during trading, a decline of 36% from the previous session’s volume of 74,244 shares.The stock last traded at $7.52 and had previously closed at $8.19.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th.

Kezar Life Sciences Price Performance

The company has a market cap of $541.15 million, a price-to-earnings ratio of -5.37 and a beta of 0.21. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. The company has a fifty day moving average price of $6.88 and a two-hundred day moving average price of $6.89.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($2.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. As a group, equities research analysts anticipate that Kezar Life Sciences, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KZR. Fidelis Capital Partners LLC bought a new stake in shares of Kezar Life Sciences in the 1st quarter worth about $25,000. Mackenzie Financial Corp acquired a new position in Kezar Life Sciences in the second quarter valued at about $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Kezar Life Sciences during the second quarter worth about $63,000. Marquette Asset Management LLC acquired a new stake in shares of Kezar Life Sciences during the first quarter worth approximately $114,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares during the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.